Vessel wall apoptosis and atherosclerotic plaque instability

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 3, 2005, Pages 465-472

  Kavurma, M M ^a   Bhindi, R ^a   Lowe, H C ^a   Chesterman, C ^a   Khachigian, Levon M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Apoptosis; Atherosclerotic plaques; Endothelial cells; Macrophages; Plaque instability; Smooth muscle cells

Indexed keywords

CASPASE 10; CASPASE 8; LUTETIUM TEXAPHYRIN; PROTEINASE;

APOPTOSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; LYSOSOME; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; ARTERIOSCLEROSIS; ARTERY; PATHOLOGY; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

APOPTOSIS; ARTERIES; ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR;

EID: 22744454646     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01120.x     Document Type: Review

References (93)

1. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the unstable plaque. Prog Cardiovascular Dis 2002; 44: 349-56.
2. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-82.
3. Virmani R, Kolodgie FD, Burke AP, Färb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-75.
4. Kockx MM, Herman AG. Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc Res 2000; 45: 736-46.
5. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-9.
6. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003; 41: S15-22.
7. Felton CV, Crook D, Davies MJ, Oliver MF. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol 1997; 17: 1337-45.
8. Laine P, Kaartinen M, Penttila A, Panula P, Paavonen T, Kovanen PT. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 1999; 99: 361-9.
9. Burleigh MC, Briggs AD, Lendon CL, Davies MJ, Born GV, Richardson PD. Collagen types I and III, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: span-wise variations. Atherosclerosis 1992; 96: 71-81.
10. Geng YJ. Molecular signal transduction in vascular cell apoptosis. Cell Res 2001; 11: 253-64.
11. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57.
12. Lazebnik YA, Cole S, Cooke CA, Nelson WG, Earnshaw WC. Nuclear events of apoptosis in vitro in cell-free mitotic extracts: a model system for analysis of the active phase of apoptosis. J Cell Biol 1993; 123: 7-22.
13. Kaufmann SH, Hengartner MO. Programmed cell death: alive and well in the new millennium. Trends Cell Biol 2001; 11: 526-34.
14. Li D, Liu L, Chen H, Sawamura T, Ranganathan S, Mehta JL. LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 2003; 107: 264-70.
15. Tricot O, Mallat Z, Heymes C, Belmin J, Leseche G, Tedgui A. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation 2000; 101: 2450-3.
16. Casscells W, Naghavi M, Willerson JT. Vulnerable atherosclerotic plaque: a multifocal disease. Circulation 2003; 107: 2072-5.
17. Maseri A, Fuster V. Is there a vulnerable plaque? Circulation 2003; 107: 2068-71.
18. Sata M, Walsh K. Oxidized LDL activates fas-mediated endothelial cell apoptosis. J Clin Invest 1998; 102: 1682-9.
19. Sata M, Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP. J Biol Chem 1998; 273: 33103-6.
20. Farber A, Kitzmiller T, Morganelli PM, Pfeiffer J, Groveman D, Wagner RJ, Cronenwett JL, Powell RJ. A caspase inhibitor decreases oxidized low-density lipoprotein-induced apoptosis in bovine endothelial cells. J Surg Res 1999; 85: 323-30.
21. Chen CH, Jiang T, Yang JH, Jiang W, Lu J, Marathe GK, Pownall HJ, Ballantyne CM, McIntyre TM, Henry PD, Yang CY. Lowdensity lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 2003; 107: 2102-8.
22. Boyle JJ, Weissberg PL, Bennett MR. Human macrophage-induced vascular smooth muscle cell apoptosis requires NO enhancement of Fas/Fas-L interactions. Arterioscler Thromb Vasc Biol 2002; 22: 1624-30.
23. Boyle JJ, Bowyer DE, Weissberg PL, Bennett MR. Human blood-derived macrophages induce apoptosis in human plaque-derived vascular smooth muscle cells by Fas-ligand/Fas interactions. Atheroscler Thromb Vasc Biol 2001; 21: 1402-7.
24. Kolodgie FD, Narula J, Burke AP, Haider N, Farb A, Hui-Liang Y, Smialek J, Virmani R. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol 2000; 157: 1259-68.
25. Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ Res 2000; 87: 184-8.
26. Ball RY, Stowers EC, Burton JH, Cary NR, Skepper JN, Mitchinson MJ. Evidence that the death of macrophage foam cells contributes to the lipid core of atheroma. Atherosclerosis 1995; 114: 45-54.
27. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, Sukhova GK, Lee RT. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996; 7: 330-5.
28. Tabas I. Apoptosis and plaque destabilization in atherosclerosis: the role of macrophage apoptosis induced by cholesterol. Cell Death Differ 2004; 11: S12-6.
29. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989; 135: 169-75.
30. Inagaki Y, Yamagishi S, Amano S, Okamoto T, Koga K, Makita Z. Interferon-gamma-induced apoptosis and activation of THP-1 macrophages. Life Sci 2002; 71: 2499-508.
31. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001; 89: E41-5.
32. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598-603.
33. Rapp JH, Connor WE, Lin DS, Inahara T, Porter JM. Lipids of human atherosclerotic plaques and xanthomas: clues to the mechanism of plaque progression. J Lipid Res 1983; 24: 1329-35.
34. Yao PM, Tabas I. Free cholesterol loading of macrophages induces apoptosis involving the Fas pathway. J Biol Chem 2000; 275: 23807-13.
35. Yao PM, Tabas I. Free cholesterol loading of macrophages is associated with widespread mitochondrial dysfunction and activation of the mitochondrial apoptosis pathway. J Biol Chem 2001; 276: 42468-76.
36. Fazio S, Major AS, Swift LL, Cleaves LA, Accad M, Linton MF, Farese RVJ. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest 2001; 107: 163-71.
37. Kellner-Weibel G, Yancey PG, Jerome WG, Walser T, Mason RP, Phillips MC, Rothblat GH. Crystallization of free cholesterol in model macrophage foam cells. Arterioscler Thromb Vasc Biol 1999; 19: 1891-8.
38. Tangirala RK, Jerome WG, Jones NL, Small DM, Johnson WJ, Click JM, Mahlberg FH, Rothblat GH. Formation of cholesterol monohydrate crystals in macrophage-derived foam cells. J Lipid Res 1994; 35: 93-104.
39. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316-25.
40. Geng YJ, Phillips JE, Mason RP, Casscells SW. Cholesterol crystallization and macrophage apoptosis: implication for atherosclerotic plaque instability and rupture. Biochem Pharmacol 2003; 66: 1485-92.
41. Li W, Dalen H, Eaton JW, Yuan XM. Apoptotic death of inflammatory cells in human atheroma. Arterioscler Thromb Vasc Biol 2001; 21: 1124-30.
42. Libby P, Geng YJ, Sukhova GK, Simon DI, Lee RT. Molecular determinants of atherosclerotic plaque vulnerability. Ann NY Acad Sci 1997; 811: 134-42.
43. O'Sullivan M, Scott SD, McCarthy N, Figg N, Shapiro LM, Kirkpatrick P, Bennett MR. Differential cyclin E expression in human in-stent stenosis smooth muscle cells identifies targets for selective anti-restenosis therapy. Cardiovasc Res 2003; 60: 673-83.
44. Patel VA, Zhang QJ, Siddle K, Soos MA, Goddard M, Weissberg PL, Bennett MR. Defect in insulin-like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells is mediated by reduced surface binding and signaling. Circ Res 2001; 88: 895-902.
45. Bauriedel G, Hutter R, Welsch U, Bach R, Sievert H, Luderitz B. Role of smooth muscle cell death in advanced coronary primary lesions: implications for plaque instability. Cardiovasc Res 1999; 41: 480-8.
46. Kockx MM, De Meyer GRY, Muhring J, Jacob W, Bult H, Herman AG. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation 1998; 97: 2307-15.
47. Cai W, Devaux B, Schaper W, Schaper J. The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions. Atherosclerosis 1997; 131: 177-86.
48. Geng YJ, Henderson LE, Levesque EB, Muszynski M, Libby P. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2200-8.
49. Mayr M, Xu Q. Smooth muscle cell apoptosis in arteriosclerosis. Exp Gerontol 2001; 36: 969-87.
50. Hansson GK. Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol 1997; 8: 301-11.
51. Geng YJ, Liao H-S, Macgovern J. Expression of FasL in advanced human atherosclerotic lesions: implications for co-occurrence of immunocytoxicity and immune privilege. Circulation 1998; 98 (Suppl. I): 1-48.
52. Sata M, Perlman H, Muruve DA, Silver M, Ikebe M, Libermann TA, Oettgen P, Walsh K. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc Natl Acad Sci USA 1998; 95: 1213-17.
53. Shimizu M, Fukuo K, Nagata S, Suhara T, Okuro M, Fujii K, Higashino Y, Mogi M, Hatanaka Y, Ogihara T. Increased plasma levels of the soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina pectoris. J Am Coll Cardiol 2002; 39: 585-90.
54. Okura T, Watanabe S, Jiang Y, Nakamura M, Takata Y, Yang ZH, Kohara K, Kitami Y, Hiwada K. Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens 2002; 20: 895-8.
55. Martin-Ventura JL, Blanco-Colio LM, Munoz-Garcia B, Gomez-Hernandez A, Arribas A, Ortega L, Tunon J, Egido J. NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Stroke 2004; 35: 458-63.
56. Kavurma MM, Bobryshev U, Khachigian LM. Ets-1 positively regulates Fas ligand transcription via co-operative interactions with Sp1. J Biol Chem 2002; 277: 36244-52.
57. Kavurma MM, Santiago FS, Bonfoco E, Khachigian LM. Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement. J Biol Chem 2001; 276: 4964-71.
58. Bennett MR, Littlewood TD, Schwartz SM, Weissberg PL. Increased sensitivity to human vascular smooth muscle cells from atherosclerotic plaques to p53-mediated apoptosis. Circ Res 1997; 81: 591-9.
59. von der Thusen JH, van Vlijmen BJ, Hoeben RC, Kockx MM, Havekes LM, van Berkel TJ, Biessen EA. Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53. Circulation 2002; 105: 2064-70.
60. Brady HJ, Gil-Gomez G. Bax. The pro-apoptotic Bcl-2 family member, Bax. Int J Biochem Cell Biol 1998; 30: 647-50.
61. Hsieh JK, Kletsas D, Clunn G, Hughes AD, Schachter M, Demoliou-Mason C. p53, 21(WAF1/CIP1), and MDM2 involvement in proliferation and apoptosis in an in vitro model of conditionally immortalized human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20: 636-44.
62. Sun SY, Yue P, Hong WK, Lotan R. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 2000; 60: 6537-43.
63. de la Monte SM, Lu BX, Sohn YK, Etienne D, Kraft J, Ganju N, Wands JR. Aberrant expression of nitric oxide synthase III in Alzheimer's disease: relevance to cerebral vasculopathy and neurodegeneration. Neurobiol Aging 2000; 21: 309-19.
64. Fukuo K, Hata S, Suhara T, Nakahashi T, Shinto Y, Tsujimoto Y, Morimoto S, Ogihara T. Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Hypertension 1996; 27: 823-6.
65. Okura Y, Brink M, Itabe H, Scheidegger KJ, Kalangos A, Delafontaine P. Oxidized low-density lipoprotein is associated with apoptosis of vascular smooth muscle cells in human atherosclerotic plaques. Circulation 2000; 102: 2680-6.
66. Kataoka H, Kume N, Miyamoto S, Minami M, Morimoto M, Hayashida K, Hashimoto N, Kita T. Oxidized LDL modulates Bax/Bcl-2 through the lectinlike Ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001; 21: 955-60.
67. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89: 2429-42.
68. Aupeix K, Toti F, Satta N, Bischoff P, Freyssinet JM. Oyxsterols induce membrane procoagulant activity in monocytic THP-1 cells. Biochem J 1996; 314: 1027-33.
69. Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, Mehran R, Sharma SK, Nemerson Y, Fuster V, Fallon JT. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94: 3090-7.
70. Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Eschwege V, Hedman H, Freyssinet JM. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 1994; 153: 3245-55.
71. Mirshahi F, Vasse M, Tedgui A, Li H, Merval R, Legrand E, Vannier JP, Soria J, Soria C. Oncostatin M induces procoagulant activity in human vascular smooth muscle cells by modulating the balance between tissue factor and tissue factor pathway inhibitor. Blood Coagul Fibrinol 2002; 13: 449-55.
72. Flynn PD, Byrne CD, Baglin TP, Weissberg PL, Bennett MR. Thrombin generation by apoptotic vascular smooth muscle cells. Blood 1997; 89: 4378-84.
73. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99: 348-53.
74. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88: 186-93.
75. Casciola-Rosen L, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA 1996; 93: 1624-9.
76. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000; 407: 810-16.
77. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 2003; 91: B4-8.
78. Ambrose JA, Martinez EE. A new paradigm for plaque stabilization. Circulation 2002; 105: 2000-4.
79. Skaletz-Rorowski A, Walsh K. Statin therapy and angiogenesis. Curr Opin Lipidol 2003; 14: 599-603.
80. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-33.
81. Aikawa M, Libby P. The vulnerable atherosclerotic plaque. Pathogenesis and therapeutic approach. Cardiovasc Pathol 2004; 13: 125-38.
82. Knapp C, Huang J, Starling G, Kiener PA. Inhibitors of HMG-CoA reductase sensitise human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis 2000; 152: 217-27.
83. Bernini F, Didoni G, Bonfadini G, Bellosta S, Fumagalli R. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis 1993; 104: 19-26.
84. Vamvakopoulos JE, Green C. HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotection. BMC Cardiovasc Disord 2003; 3: 6.
85. Indolfi C, Di Lorenzo E, Rapacciuolo A, Stingone AM, Stabile E, Leccia A, Torella D, Caputo R, Ciardiello F, Tortora G, Chiariello M. 8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. J Am Coll Cardiol 2000; 36: 288-93.
86. Erl W, Hristov M, Neureuter M, Yan ZQ, Hansson GK, Weber PC. HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular smooth muscle cells. Atherosclerosis 2003; 169: 251-8.
87. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C, Hernandez G, Egido J. 3-Hydroxy-3-methyl-glutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83: 490-500.
88. Baetta R, Donetti E, Comparato C, Calore M, Rossi A, Teruzzi C, Paoletti R, Fumagalli R, Soma MR. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol Res 1997; 36: 115-21.
89. Chen Z, Woodburn KW, Shi C, Adelman DC, Rogers C, Simon DI. Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells. Arterioscler Thromb Vasc Biol 2001; 21: 759-64.
90. Kereiakes DJ, Szyniszewski AM, Wahr D, Herrmann HC, Simon DI, Rogers C, Kramer P, Shear W, Yeung AC, Shunk KA, Chou TM, Popma J, Fitzgerald P, Carroll TE, Forer D, Adelman DC. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results. Circulation 2003; 108: 1310-15.
91. Hayase M, Woodbum KW, Perlroth J, Miller RA, Baumgardner W, Yock PG, Yeung A. Photoangioplasty with local motexafin lutetium delivery reduces macrophages in a rabbit post-balloon injury model. Cardiovasc Res 2001; 49: 449-55.
92. Rockson SG, Kramer P, Razavi M, Szuba A, Filardo S, Fitzgerald P, Cooke JP, Yousuf S, DeVault AR, Renschler MF, Adelman DC. Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin). Circulation 2000; 102: 2322-4.
93. Feng B, Zhang D, Kuriakose G, Devlin CM, Kockx M, Tabas I. Niemann-Pick C heterozygosity confers resistance to lesional necrosis and macrophage apoptosis in murine atherosclerosis. Proc Natl Acad Sci USA 2003; 100: 10423-8.